title: The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.
abstract: WNV has become the leading vector-borne cause of meningoencephalitis in the United States. Although the majority of WNV infections result in asymptomatic illness, approximately 20% of infections result in West Nile fever and 1% in West Nile neuroinvasive disease (WNND), which causes encephalitis, meningitis, or flaccid paralysis. The elderly are at particular risk for WNND, with more than half the cases occurring in persons older than sixty years of age. There is no licensed treatment for WNND, nor is there any licensed vaccine for humans for the prevention of WNV infection. The Laboratory of Infectious Diseases at the National Institutes of Health has developed a recombinant live attenuated WNV vaccine based on chimerization of the wild-type WNV NY99 genome with that of the live attenuated DENV-4 candidate vaccine rDEN4Δ30. The genes encoding the prM and envelope proteins of DENV-4 were replaced with those of WNV NY99 and the resultant virus was designated rWN/DEN4Δ30. The vaccine was evaluated in healthy flavivirus-naïve adult volunteers age 18-50 years in two separate studies, both of which are reported here. The first study evaluated 10³ or 10⁴ PFU of the vaccine given as a single dose; the second study evaluated 10⁵ PFU of the vaccine given as two doses 6 months apart. The vaccine was well-tolerated and immunogenic at all three doses, inducing seroconversion to WNV NY99 in 74% (10³ PFU), 75% (10⁴ PFU), and 55% (10⁵ PFU) of subjects after a single dose. A second 10⁵ PFU dose of rWN/DEN4Δ30 given 6 months after the first dose increased the seroconversion rate 89%. Based on the encouraging results from these studies, further evaluation of the candidate vaccine in adults older than 50 years of age is planned.
authors: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Electronic address: adurbin@jhsph.edu.
authors: Anna P
authors: AP
authors: Durbin
authors: Peter F
authors: PF
authors: Wright
authors: Amber
authors: A
authors: Cox
authors: Wangeci
authors: W
authors: Kagucia
authors: Daniel
authors: D
authors: Elwood
authors: Susan
authors: S
authors: Henderson
authors: Kimberli
authors: K
authors: Wanionek
authors: Jim
authors: J
authors: Speicher
authors: Stephen S
authors: SS
authors: Whitehead
authors: Alexander G
authors: AG
authors: Pletnev
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D010919:Placebos / Q000008:administration & dosage; D014481:United States; D014611:Vaccination / Q000009:adverse effects / Q000379:methods; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D053060:West Nile Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D010919:Placebos; D014613:Vaccines, Attenuated; D053060:West Nile Virus Vaccines
keywords: Clinical trial; Live attenuated WNV vaccine; West Nile virus (WNV)
references: Vector Borne Zoonotic Dis. 2008 Spring;8(1):35-9
references: 18237264
references: J Infect Dis. 2005 Mar 1;191(5):710-8
references: 15688284
references: Vaccine. 2003 Oct 1;21(27-30):4307-16
references: 14505913
references: JAMA. 2003 Jul 23;290(4):511-5
references: 12876094
references: Virology. 1999 May 10;257(2):363-72
references: 10329547
references: Hum Vaccin. 2006 Jul-Aug;2(4):167-73
references: 17012875
references: PLoS Negl Trop Dis. 2011 Aug;5(8):e1267
references: 21829748
references: Adv Virus Res. 2003;61:469-509
references: 14714441
references: Emerg Infect Dis. 2010 Mar;16(3):480-6
references: 20202424
references: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3036-41
references: 11880643
references: Vaccine. 2006 Sep 29;24(40-41):6392-404
references: 16831498
references: Emerg Infect Dis. 2003 Jul;9(7):788-93
references: 12890318
references: Virol Monogr. 1977;(16):1-132
references: 337651
references: J Virol. 2001 Sep;75(17):8259-67
references: 11483771
references: Viral Immunol. 2006 Spring;19(1):10-32
references: 16553547
references: Hum Vaccin. 2006 Nov-Dec;2(6):255-60
references: 17106267
references: Vaccine. 2008 Feb 13;26(7):882-90
references: 18207289
references: Annu Rev Med. 2006;57:181-94
references: 16409144
references: Am J Trop Med Hyg. 2001 Nov;65(5):405-13
references: 11716091
references: Virology. 2003 Sep 15;314(1):190-5
references: 14517072
references: Emerg Infect Dis. 2004 Oct;10(10):1736-44
references: 15504258
references: Vaccine. 2008 Feb 6;26(6):817-28
references: 18191005
references: Epidemiol Infect. 2013 Mar;141(3):591-5
references: 22640592
references: J Med Virol. 2011 May;83(5):910-20
references: 21360544
references: Vaccine. 2008 Aug 5;26(33):4150-9
references: 18586359
references: J Infect Dis. 2013 Mar 15;207(6):957-65
references: 23329850
references: J Virol. 2003 Jan;77(2):1653-7
references: 12502885
references: Vaccine. 2012 Oct 19;30(47):6656-64
references: 22959989
references: Vector Borne Zoonotic Dis. 2005 Spring;5(1):1-10
references: 15815144